Nexplanon Use in Women Primarily Choosing a Combined Oral Contraceptive
Launched by UNIVERSITY OF CALIFORNIA, DAVIS · Jun 5, 2020
Trial Information
Current as of May 29, 2025
Completed
Keywords
ClinConnect Summary
This study will be conducted at three sites across the United States: University of California, Davis, University of Colorado and University of Pennsylvania. Investigators will recruit women currently using COCs or intending to initiate COCs for pregnancy prevention. Each site will recruit approximately 40 women for a total of 120 subjects.
Visit 1:
Informed consent will be obtained. As part of informed consent, subjects will be educated that there is little data available on the adverse effects of combined COC and ENG implant use. The consent form will include a standardized description ...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Women 18 years and older currently using COCs or who have a COC prescription and are intending to initiate COCs for contraception
- Exclusion Criteria:
- • Women who have contraindications to using a COC or a contraceptive implant (Category 3 or 4 in the CDC Medical Eligibility Criteria \[MEC\])
- • Because the CDC MEC are continuously revised, the most updated criteria will be used (http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5904a3.htm)
- • Women who are currently participating in a clinical trial or have participated within the past 30 days.
- • Less than 2 weeks from the end of a pregnancy.
About University Of California, Davis
The University of California, Davis (UC Davis) is a leading research institution renowned for its commitment to advancing healthcare through innovative clinical trials and studies. With a strong focus on interdisciplinary collaboration, UC Davis leverages its extensive expertise in medical research, education, and patient care to drive breakthroughs in various fields, including medicine, public health, and agriculture. The university's clinical trial programs emphasize rigorous scientific methodology and ethical standards, aiming to translate research findings into impactful treatments and improved patient outcomes. Through its state-of-the-art facilities and a dedicated team of researchers and healthcare professionals, UC Davis is at the forefront of transforming healthcare practices and addressing critical health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
Sacramento, California, United States
Denver, Colorado, United States
Patients applied
Trial Officials
Melissa C Matulich, MD MAS
Principal Investigator
University of California, Davis
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials